Treatment of drug-resistant TB at clinics a success

Treating patients with drug-resistant tuberculosis (TB) at clinics closer to their homes instead of in hospitals, which are often further away, is 42% cheaper as well as better for patients’ quality of life, according to a new report released by Médecins Sans Frontières (MSF) ahead of World TB Day on March 24.

Each year about 15 000 cases of drug-resistant TB (DR-TB) are diagnosed in South Africa; the highest number of cases in the world behind India. It requires a minimum of 20 months of treatment, which includes six months of daily injections and up to 20 tablets a day that can lead to serious side-effects like deafness.

Traditionally, DR-TB patients are treated in hospital for at least six months because the complex condition requires expertise not usually found in primary healthcare settings like clinics. But in 2007 Médecins Sans Frontières, working with the provincial health department, began a pilot project to decentralise DR-TB services in Khayelitsha, Cape Town.

Eliminating transmission
Since the beginning of the pilot project more than 90% of patients with DR-TB are started on treatment, according to the MSF report.

“This is much higher than the rest of the country where fewer than 50% of DR-TB cases are actually initiated on treatment,” said the co-ordinator of the Khayelitsha project, Lynne Wilkinson. “The most important thing is to get people started on treatment because that is when they stop being infectious and won’t transmit DR-TB to people around them.”

Resistance can develop when antibiotics are not taken correctly or TB treatments are stopped before the end of a drug course. But, according to the report, about half of the DR-TB cases in Khayelitsha are new TB cases, which means those people were directly infected with the drug-resistant strain.

Decentralisation argument
Treating DR-TB in hospital “removes a patient from their support base like family and friends as well as trusted health workers in local clinics who the patient may have a bond with,” said Wilkinson.

Patients are less likely to seek treatment if they don’t want to be in hospital and those who have jobs lose valuable time away from work, she said. “They would rather sit in their communities remaining infectious,” she added.

Norbert Ndjeka, the head of TB for the health department, says there are only 2 500 hospital beds for people with DR-TB – 12 500 short of the estimated need.

“Not only is hospitalisation of patients who are not very sick unnecessary and expensive, but there aren’t enough beds, so they are put on waiting lists until one becomes available – again remaining infectious in their communities and driving up the epidemic,” said Wilkinson.


The health department announced a decentralisation policy in 2011 but has been slow to implement it; four years later the country has only about 70 decentralised sites with staff trained to diagnose and treat DR-TB, according to MSF.

Positive results
In his budget vote speech earlier this year, Health Minister Aaron Motsoaledi said the number of decentralised sites would be increased to 2 500.

About half of the patients in the Khayelitsha project are cured or have nearly completed treatment – a similar treatment success rate to the rest of the country. But, according to the MSF report, this is largely a result of the treatment being “toxic”, “lengthy” and “poorly efficacious”.

The report authors noted that, “even with treatment success rates remaining near 50%, a greater number of prevalent cases are being successfully treated than before 2007, with [a] potential impact on the rate of ongoing DR-TB transmission in the community”.

MSF handed the project over to the provincial health department in 2013.

“If there is a cost-saving of 42% by treating patients closer to home instead of in hospital, we can use that money to capacitate more primary health facilities to treat DR-TB patients and, in the end, we can afford to put many more patients on treatment,” said Wilkinson.

These are unprecedented times, and the role of media to tell and record the story of South Africa as it develops is more important than ever. But it comes at a cost. Advertisers are cancelling campaigns, and our live events have come to an abrupt halt. Our income has been slashed.

The Mail & Guardian is a proud news publisher with roots stretching back 35 years. We’ve survived thanks to the support of our readers, we will need you to help us get through this.

To help us ensure another 35 future years of fiercely independent journalism, please subscribe.

Advertising

Mapisa-Nqakula ‘regrets confusion’ after contradictory statements on Khosa case

The minister’s media statement follows a letter from Khosa’s attorneys that they were considering a perjury charge or a complaint with the Public Protector

Capture claims plague new private-security bargaining council

Unhappy members of the National Bargaining Council for the Private Security Sector say corporate governance standards are being flouted

The backlogs, denials and future of testing Covid-19

The National Health Laboratory Services finally admitted to a bottleneck last week, after denying there were any issues since April. According to the service, the backlog of 80 000 tests started in the first week of May
Advertising

press releases

Loading latest Press Releases…

The best local and international journalism

handpicked and in your inbox every weekday